Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial

Authors:

Abstract
No abstract available
Funding Information
  • Bristol-Myers Squibb
  • Memorial Sloan-Kettering Cancer Center (P30 CA008748)

This publication has 38 references indexed in Scilit: